UPDATE: BMO Capital Starts Pfizer (PFE) at Outperform

Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis

November 18, 2021 1:30 PM EST

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved XELJANZ® (tofacitinib) 5 mg twice daily for the treatment of adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.

XELJANZ is the first and only oral Janus kinase (JAK) inhibitor approved for five indications... More

Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative

November 18, 2021 7:00 AM EST

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need (including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer), today announced that Pfizer Inc. (NYSE: PFE) has made a $15 million equity investment in the company as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs. Pursuant to a securities purchase agreement between the parties, Pfizer purchased 2.4 million shares of Cardiff Oncology's common stock at a price of $6.22 per share.

... More

Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19

November 18, 2021 6:45 AM EST

If approved or authorized, PAXLOVID (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2 Pfizer is seeking Emergency Use Authorization of PAXLOVID with the U.S. FDA and is working to submit applications to regulatory agencies around the world. The company has entered into a voluntary license agreement with the Medicines Patent Pool to help expand access in 95 low- and middle-income countries that account for approximately 53% of the worlds population, pending... More

Pfizer Completes Acquisition of Trillium Therapeutics

November 17, 2021 9:40 AM EST

Acquisition enhances Pfizers Oncology portfolio with addition of next-generation, investigational immuno-therapeutics for hematological malignancies

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.

As... More

Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio

November 17, 2021 6:45 AM EST

Mike McDermott named EVP Chief Global Supply Officer

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that Frank DAmelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 year distinguished career with the Company. Pfizer has initiated an external search for a new Chief Financial Officer and DAmelio has agreed to stay on board through this process and serve in a consulting role through the transition. With DAmelios planned departure, and his significant... More

Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer

November 17, 2021 1:06 AM EST

New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.
Avelumab (BAVENCIO®) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or gastroesophageal junction adenocarcinomas (neoHERIZON)neoHERIZON will assess HER-Vaxx in combination with chemotherapy with or without avelumab in HER-2 positive gastric cancer

SYDNEY, Australia., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial supply agreement with Merck KGaA, Darmstadt, Germany (ETR: MRK) and Pfizer Inc. (NYSE:... More

Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer

November 17, 2021 1:05 AM EST

New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.Avelumab (BAVENCIO®) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or gastroesophageal junction adenocarcinomas (neoHERIZON)neoHERIZON will assess HER-Vaxx in combination with chemotherapy with or without avelumab in HER-2 positive gastric cancer

SYDNEY, Australia., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial supply agreement with Merck KGaA, Darmstadt, Germany (ETR:... More

Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate

November 16, 2021 2:00 PM EST

 If approved or authorized, PAXLOVID (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2 EUA submission includes clinical data from an interim analysis of the Phase 2/3 EPIC-HR study, which demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death compared to placebo in non-hospitalized high-risk adults with COVID-19 Rolling submissions have commenced in several countries including in the United Kingdom, Australia, New Zealand and South Korea, with planned submissions to other regulatory agencies around the... More

Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries

November 16, 2021 6:45 AM EST

Agreement builds on Pfizers comprehensive strategy to work toward equitable access to COVID-19 vaccines and treatments for all people, particularly those living in the poorest parts of the world Agreement will enable qualified sub-licensees to supply countries comprising approximately 53% of the worlds population Interim data from the Phase 2/3 EPIC-HR study demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death compared to placebo in non-hospitalized high-risk adults with COVID-19 within three days of symptom onset with similar results seen within five days of symptom... More

Proactive news headlines including Cauldron Energy, European Lithium, Evolution Energy Minerals and Kiland Ltd

November 16, 2021 3:50 AM EST

Sydney, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

Cauldron Energy Ltd (ASX:CXU) has received an unexpected boost while preparing for ongoing underground drilling at Blackwood Gold Project in Victoria with visible gold observed in an area formerly excavated for access purposes only. Click hereEuropean Lithium Ltd (ASX:EUR) and Jadar Resources Ltd are progressing their partnership in southern Austria, where plans are afoot to expand the Austrian Lithium Project,... More

Proactive news headlines including Cauldron Energy, European Lithium, Evolution Energy Minerals and Kiland Ltd

November 16, 2021 3:49 AM EST

Sydney, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

Cauldron Energy Ltd (ASX:CXU) has received an unexpected boost while preparing for ongoing underground drilling at Blackwood Gold Project in Victoria with visible gold observed in an area formerly excavated for access purposes only. Click hereEuropean Lithium Ltd (ASX:EUR) and Jadar Resources Ltd are progressing their partnership in southern Austria, where plans are afoot to expand the Austrian... More